
Heron Therapeutics
Heron Therapeutics: A US-based biotech firm enhancing injectable pharmaceuticals via proprietary drug delivery tech.

Heron Therapeutics: A US-based biotech firm enhancing injectable pharmaceuticals via proprietary drug delivery tech.
Heron Therapeutics, founded in Redwood City, United States, is a biotechnology company dedicated to enhancing the therapeutic profiles of injectable pharmaceuticals through its proprietary biochronomer drug delivery technology. The company's core mission is to improve patient outcomes by reformulating existing therapies to provide better efficacy and safety. Heron Therapeutics focuses on developing best-in-class medicines that significantly improve the quality of life for patients.
Notable figures associated with Heron Therapeutics include its leadership team and board members who bring extensive experience in biotechnology and pharmaceuticals. The company has garnered significant investment from prominent biotech investors. Key achievements include the FDA approval of their products Aponvie™ and Zynrelef®, which have set new standards in post-surgical pain management. Heron Therapeutics' innovative approach has had a substantial impact on the biotech industry, particularly in the realm of drug delivery systems.
Companies similar to Heron Therapeutics include Hera Health Solutions, Halozyme Therapeutics, Xeris Biopharma Holdings and Durect.
Heron Therapeutics was founded in 1983.
Heron Therapeutics' headquarters is located in San Diego, CA, US.
Heron Therapeutics' most recent funding round was for $30M (USD) in July 2023.
As of Jul 24, 2023, Heron Therapeutics has disclosed funding of $974M (USD). Undisclosed round amounts are excluded.
Heron Therapeutics has 203 employees as of Feb 6, 2024.

Durect
durect.com